Avalo: Edison Open House Healthcare 2022

Avalo: Edison Open House Healthcare 2022

Avalo Therapeutics — 1 video in collection

Avalo is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in the areas of immunology, immuno-oncology and rare disease.

• Tell us about the company.
• How many programmes are you running at the moment?
• Which programmes should investors be focusing on?
• What is the unmet medical need in Crohn’s disease and how is Avalo different in this market?
• How large do you think the Crohn’s market is?
• Tell us about the recent encouraging data on Crohn’s disease.
• Is there a possibility that some people could become refractory to your drug?
• Which milestones should investors focus on in the coming year?
• Please tell us more about your close association with the Children’s Hospital of Philadelphia.


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.